RIDGEFIELD, CT – (July 28, 2021) – Thetis Pharmaceuticals (“Thetis”), a leading developer of Resolvin-based therapies for cancer and autoimmune diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to TP-317 for treatment of pancreatic cancer. “TP-317 is a first-in-class Resolvin E1 therapy that offers a transformative new […]
Category: News
Thetis Pharmaceuticals Launches Resolvin E1 Cancer Program and Scientific Advisory Board
RIDGEFIELD, CT – (July 8, 2021) – Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company developing Resolvin-based therapies, announced today the launch of a new program in cancer and the formation of a scientific advisory board (SAB) with several prominent cancer researchers and industry veterans. The company’s lead program, TP-317, is a first-in-class Resolvin E1 […]
Thetis Pharmaceuticals Announces Completion of Pre-IND Meeting with FDA for Development of its Resolvin E1 Candidate, TP-317, for Inflammatory Bowel Disease
TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease RIDGEFIELD, CT – (January 20, 2021) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it completed a Pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration […]
Thetis Pharmaceuticals Receives Orphan Drug Designation for Resolvin E1 Program in Pediatric Ulcerative Colitis
Thetis’ drug candidate TP-317 is a first-in-class small molecule oral therapy in development for inflammatory bowel disease (IBD) RIDGEFIELD, CT – (December 14, 2020) – Thetis Pharmaceuticals (“Thetis”), a biopharmaceutical company developing novel therapies for autoimmune and inflammatory disorders, announced today that it has received U.S. Food and Drug Administration orphan drug designation for TP-317 […]
Thetis Pharmaceuticals Announces Patent Issuance in Europe for its Resolvin E1 candidate, TP-317, for Inflammatory Bowel Disease
TP-317 is a first-in-class small molecule oral therapy in development for ulcerative colitis and Crohn’s Disease RIDGEFIELD, CT – (July 23, 2020) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on developing Resolvin-based therapies for inflammatory diseases, announced today that the European Patent Office has granted patent EP 3157936 providing composition of matter protection […]
